Christoffer Rosenblad

Chief Executive Officer, Xvivo Perfusion

Search every verified Christoffer Rosenblad interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Christoffer Rosenblad, CEO of Xvivo Perfusion, discussed the company’s second-quarter 2026 financial results during an earnings call. He reported a 36% organic topline growth compared to the same quarter the previous year, with sales in line with the prior quarter. Rosenblad stated that the company’s cash flow was neutral for the third consecutive quarter, and he expressed a belief that the company could end 2026 cash positive for the first time in its history. Rosenblad highlighted clinical evidence from a European randomized control trial in heart transplantation, which he said showed superior endpoints and a link between preservation method, severe PDD reduction, and reduced one-year mortality. He noted that the company is investing heavily in regulatory applications for heart globally and liver in the U.S., as well as in commercial capability and production scale-up. Regarding the upcoming launch of a "hard" product, Rosenblad indicated that the company expects to add approximately 10 to 13 commercial headcounts in the U.S. during the next year, including sales, customer support, technical support, and clinical training roles.